Glecirasib plus ivonescimab for first-line kras g12c lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of two drugs: one that targets a specific genetic change in your cancer (KRAS G12C) and one that boosts your immune system to fight the cancer. It's for people who haven't had treatment for advanced or metastatic lung cancer yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC) that is either stage 3 (not treatable with curative chemo-radiation) or stage 4 (metastatic).
- Your cancer has a specific genetic marker called KRAS G12C.
- Your PD-L1 level is 1% or higher (a test that helps predict response to immunotherapy).
- You have not had systemic treatment (such as chemotherapy or immunotherapy) for this cancer, except for adjuvant therapy completed more than 6 months ago.
- You are generally able to care for yourself (ECOG status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests two new drugs together (sosimerasib and IN10018) as a first treatment for people with a specific type of lung cancer that has the KRAS G12C gene change. The goal is to see if the combination works better than standard therapy.
This study tests a new combination of drugs before surgery for people with a certain type of lung cancer (KRAS G12C). The goal is to see if these drugs can shrink the tumor and improve chances of successful surgery.
This trial tests a new combination of two targeted medicines for advanced non-small cell lung cancer with a specific gene change (KRAS G12C). The goal is to see if this combination can shrink or slow the cancer.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.